Abrocitinib (CIBINQO) in Atopic Dermatitis
Criteria for Use
August 2025

VA Pharmacy Benefits Management Services and National Formulary Committee

The following recommendations are based on medical evidence, clinician input, and expert opinion. The content of the document is dynamic and will be revised as new information becomes available. The purpose of this document is to assist practitioners in clinical decision-making, to standardize and improve the quality of patient care, and to promote cost-effective drug prescribing. THE CLINICIAN SHOULD USE THIS GUIDANCE AND INTERPRET IT IN THE CLINICAL CONTEXT OF THE INDIVIDUAL PATIENT. INDIVIDUAL CASES THAT ARE EXCEPTIONS TO THE EXCLUSION AND INCLUSION CRITERIA SHOULD BE ADJUDICATED AT THE LOCAL FACILITY ACCORDING TO THE POLICY AND PROCEDURES OF ITS P&T COMMITTEE AND PHARMACY SERVICES.

The Product Information should be consulted for detailed prescribing information.

Exclusion Criteria

If ANY of the following is selected, the patient will NOT meet criteria for abrocitinib.

- ☐ Uncontrolled active infection (however, abrocitinib may be started / restarted once treatment for the infection is initiated).
- ☐ Untreated latent or active tuberculosis.
- ☐ Hepatitis B surface antigen (HBsAg)-positive and not on antiviral prophylaxis.^1 Abrocitinib may be initiated after starting antiviral prophylaxis.
- ☐ Untreated HIV infection. Treated, well-controlled, asymptomatic HIV-positive patients can be treated with abrocitinib.
- ☐ Congenital or acquired immunodeficiency.
- ☐ Malignancy in the previous 5 years other than successfully treated nonmelanoma skin cancer or successfully treated cervical cancer, unless it is documented that the treating dermatologist and oncologist agree that risk-benefits favor using the drug.
- ☐ Thrombosis or major adverse cardiovascular events in which potential harms are expected to outweigh the anticipated benefits.
- ☐ Platelets < 150,000/mm^3, lymphocytes < 500 cells/mm^3 confirmed by repeat testing, neutrophils < 1000 cells/mm^3, or hemoglobin < 8 g/dL. (Abrocitinib may be started / restarted once values normalize).
- ☐ Severe renal impairment (eGFR 15–29 mL/min) or end-stage renal disease (eGFR < 15 mL/min).
- ☐ Severe hepatic impairment (Child-Pugh class C).
- ☐ Concomitant therapy with other JAK inhibitors, biologic disease-modifying antirheumatic drugs (bDMARDs), other immunosuppressive biologics, or potent immunosuppressants (e.g., azathioprine, cyclosporine, tacrolimus).^2
- ☐ Concomitant therapy with moderate to strong inhibitors of both CYP2C19 and CYP2C9 (e.g., fluconazole).
- ☐ Concomitant therapy with strong inducers of CYP2C19 or CYP2C9 (e.g., rifampin).
- ☐ Antiplatelets in the first 3 months of abrocitinib therapy except for low-dose aspirin (≤ 81 mg/day)
- ☐ Pregnancy.
- ☐ Breastfeeding

☐ Administration of live or live-attenuated vaccines within 2 weeks before initiation of abrocitinib therapy.^3

Inclusion Criteria

ALL of the following criteria must be fulfilled.

☐ Diagnosis of chronic atopic dermatitis.

☐ Prescribed and monitored by a VA/VA Community Care dermatologist, immunologist, or allergist, OR a locally designated expert in the management of atopic dermatitis *in consultation with* a VA/VA Community Care dermatologist.

☐ Assessment of moderate to severe atopic dermatitis in the last 2 weeks as determined by either a gestalt assessment of "moderate" or "severe" OR Eczema Area and Severity Index (EASI) ≥ 16 (scale 0–72).^4

☐ Offered all age-appropriate vaccinations prior to initiating therapy.

☐ Completed tuberculosis (TB) test using tuberculin skin test or interferon-gamma release assay [IGRA].^5

☐ Completed hepatitis B screening (HBsAg, total antibody to hepatitis B core antigen [anti-HBc] and antibody to hepatitis B surface antigen [anti-HBs]).^5

☐ Current or past completion of hepatitis C screening. (Abrocitinib may be initiated while waiting for test results.)^5

☐ **Dupilumab,^6 tralokinumab-ldrm,^6 lebrikizumab-lbkz,^6 OR nemolizumab-ilto^7 therapy** is medically inadvisable,^8 not tolerated, not adequate, or lost response.

Additional Inclusion Criteria

Select if appropriate.

☐ If HBsAg-negative but anti-HBc-positive and consult is deemed indicated: A GI/liver or infectious diseases expert has been (e-)consulted for advice on whether to start antiviral prophylaxis or to preemptively monitor for HBV reactivation.

☐ For females who can become pregnant and patients with partners who can become pregnant: Counseling provided on potential risks vs benefits of treatment and the use of effective contraception.

☐ For females who are breastfeeding/providing breastmilk to an infant: Counseling provided on potential risks vs benefits of treatment.

Other Justification

☐ _____

Footnotes

[1] Antiviral prophylaxis for HBV: Agents with high genetic barrier to resistance such as entecavir or tenofovir should be used.

[2] Except overlaps during treatment transition. Co-use with antirheumatic doses of conventional immunomodulators such as methotrexate or leflunomide is acceptable.

[3] When possible, vaccinations should be updated before the patient initiates abrocitinib. Unless contraindicated, recombinant zoster (SHINGRIX equivalent) vaccine should be completed or at least initiated by the end of the first year of treatment with abrocitinib, preferably when abrocitinib dosage is low, disease is stable, or at other times when a robust immune response to vaccination can be expected.

[4] When practical, two other instruments (SCORing Atopic Dermatitis [SCORAD] index and the Patient Oriented Eczema Measure (POEM) may be considered. Gestault Assessment refers to the physician's global gestalt impression based on expert clinical judgment rather than an instrument rating score.

[5] Routine retesting is not required for prescription renewals. Retesting in high-risk patients should be considered.

[6] Adequate therapeutic trial: NO response after 12 weeks or inadequate response after 16 weeks.

[7] Adequate therapeutic trial for nemolizumab-ilto: NO response after 16 weeks or inadequate response after 24 weeks.

[8] If dupilumab, tralokinumab-ldrm, lebrikizumab-lbkz, or nemolizumab-ilto is contraindicated, the therapies required prior to those biologic agents should still be tried before abrocitinib. See specific biologic criteria for details.

Revised: August 2025, August 2024
Original: February 2023
Contact: Francine Goodman, National Program Manager, VA Pharmacy Benefits Management Services – Formlary Management (12PBM)